Targeting both IL-4- and IL-13-mediated signaling simultaneously has proved successful and has led to the approval of the first IL-4-/IL-13-targeted biologic agent for the treatment of CRSwNP: dupilumab. Here, IL4 is linked to chronic rhinosinusitis with nasal polyps.